Janssen applies for FDA approval for Genmab drug
Teclistamab, which is based on Genmab's duobody technology platform, will now be evaluated by the FDA.
by mikkel aabenhus hemmingsen, translated by catherine brett
Genmab's partner Janssen has applied for approval for its bone marrow cancer treatment teclistamab from the US Food and Drug Administration (FDA).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA approves another Darzalex combination treatment
For subscribers
